NCT00017589View on ClinicalTrials.gov

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

December 31, 2000

Study Completion Date

May 31, 2006

Conditions

Leukemia

Interventions

BIOLOGICAL

oblimersen sodium

DRUG

gemtuzumab ozogamicin

Trial Locations (1)

07922

Genta Incorporated, Berkeley Heights

Sponsors

Lead Sponsor

Genta Incorporated

All Listed Sponsors

lead

Genta Incorporated

INDUSTRY

NCT00017589 - Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter